Cargando…

Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study

To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three con...

Descripción completa

Detalles Bibliográficos
Autores principales: Suffritti, Chiara, Gualtierotti, Roberta, Arcudi, Sara, Ciavarella, Alessandro, Novembrino, Cristina, Lecchi, Anna, La Marca, Silvia, Padovan, Lidia, Scalambrino, Erica, Clerici, Marigrazia, Bono, Patrizia, Ceriotti, Ferruccio, Muscatello, Antonio, Siboni, Simona Maria, Peyvandi, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487950/
https://www.ncbi.nlm.nih.gov/pubmed/37685542
http://dx.doi.org/10.3390/jcm12175475
_version_ 1785103362956460032
author Suffritti, Chiara
Gualtierotti, Roberta
Arcudi, Sara
Ciavarella, Alessandro
Novembrino, Cristina
Lecchi, Anna
La Marca, Silvia
Padovan, Lidia
Scalambrino, Erica
Clerici, Marigrazia
Bono, Patrizia
Ceriotti, Ferruccio
Muscatello, Antonio
Siboni, Simona Maria
Peyvandi, Flora
author_facet Suffritti, Chiara
Gualtierotti, Roberta
Arcudi, Sara
Ciavarella, Alessandro
Novembrino, Cristina
Lecchi, Anna
La Marca, Silvia
Padovan, Lidia
Scalambrino, Erica
Clerici, Marigrazia
Bono, Patrizia
Ceriotti, Ferruccio
Muscatello, Antonio
Siboni, Simona Maria
Peyvandi, Flora
author_sort Suffritti, Chiara
collection PubMed
description To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three consecutive adult HIV-positive patients with hemophilia were included. Blood was collected before and two weeks after vaccination. We measured anti-SARS-CoV-2 spike protein antibodies to assess immunogenicity; circulating biomarkers of coagulation (protein C and D-dimer), endothelial perturbation (von Willebrand factor (VWF)) and anti-Platelet Factor 4 (PF4) antibodies were analyzed. Flow-based analysis of thrombus formation was performed in nine patients using a flow-chamber device. Two weeks after completing the vaccination schedule, all patients had anti-spike antibodies values consistent with an effective immunization. Mean (±standard deviation) basal values of protein C and VWF (106 ± 21% and 171 ± 45%, respectively) were not significantly different from data obtained two weeks after the second dose (103 ± 20%, 162 ± 43%, respectively). D-dimer median values (interquartile range) were not significantly different at baseline (442 (603–142) ng/mL) and after the second dose (477 (654–262) ng/mL). Anti-PF4 antibodies were detected in three patients with no associated clinical manifestations. No significant differences were found in flow-based analysis of thrombus formation. Our data demonstrate that in HIV-positive patients with hemophilia, SARS-CoV-2 vaccination is effective and safe, with no effects on coagulation and endothelial perturbation.
format Online
Article
Text
id pubmed-10487950
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104879502023-09-09 Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study Suffritti, Chiara Gualtierotti, Roberta Arcudi, Sara Ciavarella, Alessandro Novembrino, Cristina Lecchi, Anna La Marca, Silvia Padovan, Lidia Scalambrino, Erica Clerici, Marigrazia Bono, Patrizia Ceriotti, Ferruccio Muscatello, Antonio Siboni, Simona Maria Peyvandi, Flora J Clin Med Brief Report To characterize the immunogenicity of mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine in HIV-positive hemophilic patients during the third COVID-19 wave in Italy and to investigate biomarkers of coagulation and endothelial perturbation before and after complete vaccination schedule, twenty-three consecutive adult HIV-positive patients with hemophilia were included. Blood was collected before and two weeks after vaccination. We measured anti-SARS-CoV-2 spike protein antibodies to assess immunogenicity; circulating biomarkers of coagulation (protein C and D-dimer), endothelial perturbation (von Willebrand factor (VWF)) and anti-Platelet Factor 4 (PF4) antibodies were analyzed. Flow-based analysis of thrombus formation was performed in nine patients using a flow-chamber device. Two weeks after completing the vaccination schedule, all patients had anti-spike antibodies values consistent with an effective immunization. Mean (±standard deviation) basal values of protein C and VWF (106 ± 21% and 171 ± 45%, respectively) were not significantly different from data obtained two weeks after the second dose (103 ± 20%, 162 ± 43%, respectively). D-dimer median values (interquartile range) were not significantly different at baseline (442 (603–142) ng/mL) and after the second dose (477 (654–262) ng/mL). Anti-PF4 antibodies were detected in three patients with no associated clinical manifestations. No significant differences were found in flow-based analysis of thrombus formation. Our data demonstrate that in HIV-positive patients with hemophilia, SARS-CoV-2 vaccination is effective and safe, with no effects on coagulation and endothelial perturbation. MDPI 2023-08-23 /pmc/articles/PMC10487950/ /pubmed/37685542 http://dx.doi.org/10.3390/jcm12175475 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Suffritti, Chiara
Gualtierotti, Roberta
Arcudi, Sara
Ciavarella, Alessandro
Novembrino, Cristina
Lecchi, Anna
La Marca, Silvia
Padovan, Lidia
Scalambrino, Erica
Clerici, Marigrazia
Bono, Patrizia
Ceriotti, Ferruccio
Muscatello, Antonio
Siboni, Simona Maria
Peyvandi, Flora
Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
title Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
title_full Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
title_fullStr Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
title_full_unstemmed Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
title_short Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
title_sort characterization of immunogenicity and safety of covid-19 mrna-1273 in hiv-positive italian patients with hemophilia: a prospective single-center cohort study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487950/
https://www.ncbi.nlm.nih.gov/pubmed/37685542
http://dx.doi.org/10.3390/jcm12175475
work_keys_str_mv AT suffrittichiara characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT gualtierottiroberta characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT arcudisara characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT ciavarellaalessandro characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT novembrinocristina characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT lecchianna characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT lamarcasilvia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT padovanlidia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT scalambrinoerica characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT clericimarigrazia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT bonopatrizia characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT ceriottiferruccio characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT muscatelloantonio characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT sibonisimonamaria characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy
AT peyvandiflora characterizationofimmunogenicityandsafetyofcovid19mrna1273inhivpositiveitalianpatientswithhemophiliaaprospectivesinglecentercohortstudy